Boston Scientific Corp. said Monday that it has won approval for three new coronary medical devices from the Food and Drug Administration.
Boston Scientific Corp. said Monday that it has won approval for three new coronary medical devices from the Food and Drug Administration.
In a statement, Boston Scientific said that the FDA has given the okay to market a new implantable heart defibrillator called the Confient ICD, which will be used to correct irregular heart rhythms that can lead to sudden death.
The FDA has also approved a resynchronization therapy defibrillator called the Livian CRT-D. The devices are used to treat certain types of heart failure. The agency also green lighted an upgraded version of the company's Latitude monitoring system, which allows healthcare professionals to monitor coronary devices remotely.